Skip to main content

Peer Review reports

From: Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype

Original Submission
4 Feb 2010 Submitted Original manuscript
5 Feb 2010 Author responded Author comments - Junichi Kurebayashi
Resubmission - Version 2
5 Feb 2010 Submitted Manuscript version 2
28 Mar 2010 Reviewed Reviewer Report - Norma O'Donovan
29 Mar 2010 Reviewed Reviewer Report - Richard Finn
4 Apr 2010 Author responded Author comments - Junichi Kurebayashi
Resubmission - Version 3
4 Apr 2010 Submitted Manuscript version 3
6 May 2010 Reviewed Reviewer Report - Norma O'Donovan
11 May 2010 Reviewed Reviewer Report - Richard Finn
4 Jul 2010 Author responded Author comments - Junichi Kurebayashi
Resubmission - Version 4
4 Jul 2010 Submitted Manuscript version 4
4 Oct 2010 Reviewed Reviewer Report - Richard Finn
Resubmission - Version 5
Submitted Manuscript version 5
15 Oct 2010 Author responded Author comments - Junichi Kurebayashi
Resubmission - Version 6
15 Oct 2010 Submitted Manuscript version 6
Resubmission - Version 7
Submitted Manuscript version 7
15 Oct 2010 Author responded Author comments - Junichi Kurebayashi
Resubmission - Version 8
15 Oct 2010 Submitted Manuscript version 8
Publishing
20 Oct 2010 Editorially accepted
20 Oct 2010 Article published 10.1186/1471-2407-10-568

You can find further information about peer review here.

Back to article page